

THE CROATIAN ACADEMY OF SCIENCES AND ARTS
The Department of Clinical and Transplantation Immunology and
Molecular Medicine in Rijeka
THE CLINICAL HOSPITAL CENTER RIJEKA
UNIVERSITY OF RIJEKA - MEDICAL FACULTY
THE CROATIAN MEDICAL ASSOCIATION – Branch office Rijeka

Sponsored by:

fritz bender stiftung 

9th Symposium

PROGRESS TOWARDS INDIVIDUALIZED CANCER THERAPEUTICS



29th June 2015.
9,00 am

University Campus Rijeka, University Departments, Lecture hall O-030,
Radmile Matejčić 2, Rijeka

Organizatori

HRVATSKA AKADEMIJA ZNANOSTI I
UMJETNOSTI

Zavod za kliničku i transplantacijsku
imunologiju i molekularnu medicinu u
Rijeci

KLINIČKI BOLNIČKI CENTAR RIJEKA

SVEUČILIŠTE U RIJECI

MEDICINSKI FAKULTET

HRVATSKI LIJEČNIČKI ZBOR –
Podružnica Rijeka

Organized by

THE CROATIAN ACADEMY OF SCIENCES
AND ARTS

The Department of Clinical and
Transplantation Immunology and Molecular
Medicine in Rijeka

THE CLINICAL HOSPITAL CENTER RIJEKA

UNIVERSITY OF RIJEKA

MEDICAL FACULTY

THE CROATIAN MEDICAL
ASSOCIATION – Branch office Rijeka

Scientific Committee

Enrico Mihich, president

Daniel Rukavina, Zvonko Kusić

Organizing Committee

Daniel Rukavina, president

Enrico Mihich, Tomislav Rukavina, Davor Štimac, Gordan Gulan

Registration: 8,00 – 9,00 h

Free admission. Participants who want a certificate from the Croatian
Medical Chamber need to register.

Refreshments during breaks and lunch are with no charge.

Parking is free and provided in the building of the Faculty
of Civil Engineering ,
Radmile Matejčić 3

Information

Željana Mikovčić, Department of Clinical and Transplantation Immunology
and Molecular Medicine, Radmile Matejčić 2, Rijeka
Phone: 051 584 826, e-mail: rimed@hazu.hr

P R O G R A M

OPENING

(9,00 – 9,30 h)

Welcome addresses

Davor Štimac, M.D., PhD., Professor, Chairman of the Clinical Hospital Center Rijeka

Tomislav Rukavina, M.D., PhD., Professor, Dean of the Medical Faculty Rijeka

Pero Lučin, M.D., PhD., Professor, Rector of the University of Rijeka

Zvonko Kusić, M.D., PhD., Professor, President of the Croatian Academy of Sciences and Arts

Opening

Hans – Peter Huber, Fritz-Bender Foundation Supervisory Board, Vice-Chairman

Welcome address

Enrico Mihich, M.D., PhD., Professor, Dana Farber Cancer Institute Boston, Boston, USA

Focus and Goals

9,30 – 11,00 h

Chairmen: Z. Werb and T. Taniguchi

Đuro Josić, PhD., Professor, University of Rijeka, Department of Biotechnology, Rijeka, Croatia

Omics methods in personalized cancer treatments

Marija Petković, M.D., PhD., Professor, University of Rijeka Medical Faculty, Clinical Hospital Center, Rijeka, Croatia

Breast cancer biotherapy treatment: individualized approach

Sanja Šale, M.D., PhD., Chief Science and Technology Officer, BICRO BIOCentre Ltd., Zagreb, Croatia

Targeted therapy for breast cancer: novel insights from lineage tracing studies

Coffee break: 11,00 - 11,30 h

11,30 – 13,15 h

Chairmen: S. Ferrone and M. Sadelain

Tadatsugu Taniguchi, PhD., Director, Max Planck-The University of Tokyo Center for Integrative Inflammation, Tokyo, Japan

Regulation of anti-tumor immune innate immune responses: implications to cancer therapeutics

Soldano Ferrone, M.D., PhD., Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, USA

Combinatorial immunotherapy eradicate both differentiated cancer cells and cancer initiating cells in solid tumors

Michel Sadelain, MD, PhD., Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA

CAR therapy and the promise of T cell engineering

Lunch with a panel of speakers: 13,15 – 14,15 h

14,15 – 16,30 h

Chairmen: J. Pawelek and R. Giavazzi

John Pawelek, PhD., Department of Dermatology and the Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA

Macrophage fusion with cancer cells as a mechanism of metastasis

Zena Werb, PhD., Professor and Vice-Chair, Dept. of Anatomy, University of California, San Francisco, CA, USA

The role of the microenvironment in cancer progression, metastasis and response to therapy

Raffaella Giavazzi, PhD., Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy

Profiling response to treatments with angiogenesis inhibitors in ovarian cancer

Kenneth Beaman, PhD., Director, Clinical Immunology Lab, Rosalind Franklin University of Medicine, Chicago, USA

Vacuolar ATPase is a unique potential target for cancer therapy

16,30 h –

Daniel Rukavina,

M.D., PhD. Professor Emeritus, Croatian Academy of Sciences and Arts, Rijeka, Croatia

Concluding remarks

Endorsed by:

